Type 2 diabetes mellitus-related genetic polymorphisms in microRNAs and microRNA target sites

Journal of Diabetes

Volumn 6, Issue 4, 2014, Pages 279-289

  Gong, Weijing ^a,b   Xiao, Di ^a,b   Ming, Guangfeng ^a,b   Yin, Jiye ^a,b   Zhou, Honghao ^a,b   Liu, Zhaoqian ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Genetic polymorphism; microRNA; microRNA target sites; Type 2 diabetes mellitus

Indexed keywords

DICER; MESSENGER RNA; MICRORNA; MICRORNA 34A; MICRORNA 657; MICRORNA 663; PEPTIDE YY; SOMATOMEDIN B RECEPTOR; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ALLELE; ARTICLE; BINDING SITE; BIOGENESIS; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME MECHANISM; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; INDEL MUTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

ANIMALS; BINDING SITES; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION REGULATION; HUMANS; MICRORNAS; POLYMORPHISM, GENETIC; RNA, MESSENGER;

EID: 84901843917     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12143     Document Type: Article

References (91)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010; 87: 4-14.
2. Yang W, Lu J, Weng J etal. Prevalence of diabetes among men and women in china. N Engl J Med. 2010; 362: 1090-1101.
3. van Dueren S, Beulens JW, van der Schouw YT, Grobbee DE, Neal B. The global burden of diabetes and its complications: An emerging pandemic. Eur J Cardiovasc Prev Rehabil. 2010; 17 (Suppl. 1): S3-8.
4. Balasubramanyam M, Aravind S, Gokulakrishnan K etal. Impaired miR-146a expression links subclinical inflammation and insulin resistance in type 2 diabetes. Mol Cell Biochem. 2011; 351: 197-205.
5. Gregory RI, Shiekhattar R. MicroRNA biogenesis and cancer. Cancer Res. 2005; 65: 3509-3512.
6. Johnnidis JB, Harris MH, Wheeler RT etal. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature. 2008; 451: 1125-1129.
7. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-297.
8. Pillai RS, Bhattacharyya SN, Artus CG etal. Inhibition of translational initiation by Let-7 microRNA in human cells. Science. 2005; 309: 1573-1576.
9. Yekta S, Shih IH, Bartel DP. MicroRNA-directed cleavage of HOXB8 mRNA. Science. 2004; 312: 75-79.
10. Giraldez AJ, Mishima Y, Rihel J etal. Zebrafish MiR-430 promotes deadenylation and clearance of maternal mRNAs. Science. 2006; 309: 1573-1576.
11. Friedman RC, Farh KK-H, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009; 19: 92-105.
12. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120: 15-20.
13. Rodriguez A, Griffiths-Jones S, Ashurst JL etal. Identification of mammalian microRNA host genes and transcription units. Genome Res. 2004; 14: 1902-1910.
14. Lee Y, Kim M, Han J etal. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004; 23: 4051-4060.
15. Liu X, Fortin K, Mourelatos Z. MicroRNAs: Biogenesis and molecular functions. Brain Pathol. 2008; 18: 113-121.
16. Han J, Lee Y, Yeom KH etal. Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. Cell. 2006; 125: 887-901.
17. Zhang X, Zeng Y. The terminal loop region controls microRNA processing by Drosha and Dicer. Nucleic Acids Res. 2010; 38: 7689-7697.
18. Hutvágner G, McLachlan J, Pasquinelli AE, Bálint E, Tuschl T, Zamore PD. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science. 2001; 293: 834-838.
19. Warf MB, Johnson WE, Bass BL. Improved annotation of C. elegans microRNAs by deep sequencing reveals structures associated with processing by Drosha and Dicer. RNA. 2011; 17: 563-577.
20. Cifuentes D, Xue H, Taylor DW etal. A novel miRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity. Science. 2010; 328: 1694-1698.
21. Lim LP, Lau NC, Garrett-Engele P etal. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005; 433: 769-773.
22. Saunders MA, Liang H, Li WH. Human polymorphism at microRNAs and microRNA target sites. Proc Natl Acad Sci USA. 2007; 104: 3300-3305.
23. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: The implications for cancer research. Nat Rev Cancer. 2010; 10: 389-402.
24. Ciccacci C, Di Fusco D, Cacciotti L etal. MicroRNA genetic variations: Association with type 2 diabetes. Acta Diabetol. 2013; 50: 867-872.
25. Locke JM, Lango Allen H, Harries LW. A rare SNP in pre-miR-34a is associated with increased levels of miR-34a in pancreatic beta cells. Acta Diabetol. 2014; 51: 325-329.
26. Zhou J, Peng R, Li T etal. A potentially functional polymorphism in the regulatory region of let-7a-2 is associated with an increased risk for diabetic nephropathy. Gene. 2013; 527: 456-461.
27. Hara K, Fujita H, Johnson TA etal. Genome-wide association study identifies three novel loci for type 2 diabetes. Hum Mol Genet. 2014; 23: 239-246.
28. Baroukh N, Ravier MA, Loder MK etal. MicroRNA-124a regulates Foxa2 expression and intracellular signaling in pancreatic beta-cell lines. J Biol Chem. 2007; 282: 19575-19588.
29. Lovis P, Gattesco S, Regazzi R. Regulation of the expression of components of the exocytotic machinery of insulin-secreting cells by microRNAs. Biol Chem. 2008; 389: 305-312.
30. Wu JH, Gao Y, Ren AJ etal. Altered microRNA expression profiles in retinas with diabetic retinopathy. Ophthalmic Res. 2011; 47: 195-201.
31. Qi L, Hu Y, Zhan Y etal. A SNP site in pri-miR-124 changes mature miR-124 expression but no contribution to Alzheimer's disease in a Mongolian population. Neurosci Lett. 2012; 515: 1-6.
32. Lovis P, Roggli E, Laybutt DR etal. Alterations in microRNA expression contribute to fatty acid- pancreatic β-cell dysfunction. Diabetes. 2008; 57: 2728-2736.
33. Kong L, Zhu J, Han W etal. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: A clinical study. Acta Diabetol. 2011; 48: 61-69.
34. Li S, Chen X, Zhang H etal. Differential expression of microRNAs in mouse liver under aberrant energy metabolic status. J Lipid Res. 2009; 50: 1756-1765.
35. Kim SY, Kim AY, Lee HW etal. miR-27a is a negative regulator of adipocyte differentiation via suppressing PPARgamma expression. Biochem Biophys Res Commun. 2010; 392: 323-328.
36. Lin Q, Gao Z, Alarcon RM, Ye J, Yun Z. A role of miR-27 in the regulation of adipogenesis. FEBS J. 2009; 276: 2348-2358.
37. Alisi A, Da Sacco L, Bruscalupi G etal. Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. Lab Invest. 2011; 91: 283-293.
38. Meng S, Cao JT, Zhang B, Zhou Q, Shen CX, Wang CQ. Downregulation of microRNA-126 in endothelial progenitor cells from diabetes patients, impairs their functional properties, via target gene Spred-1. J Mol Cell Cardiol. 2012; 53: 64-72.
39. Sun Q, Gu H, Zeng Y etal. Hsa-mir-27a genetic variant contributes to gastric cancer susceptibility through affecting miR-27a and target gene expression. Cancer Sci. 2010; 101: 2241-2247.
40. Yang R, Schlehe B, Hemminki K etal. A genetic variant in the pre-miR-27a oncogene is associated with a reduced familial breast cancer risk. Breast Cancer Res Treat. 2010; 121: 693-702.
41. Lei B, Gao S, Luo LF etal. A SNP in the miR-27a gene is associated with litter size in pigs. Mol Biol Rep. 2011; 38: 3725-3729.
42. Frost RJ, Olson EN. Control of glucose homeostasis and insulin sensitivity by the let-7 family of microRNAs. Proc Natl Acad Sci USA. 2011; 108: 21075-21080.
43. Xu HY, Barnes GT, Yang Q etal. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003; 112: 1821-1830.
44. Bravo-Egana V, Rosero S, Klein D etal. Inflammation-mediated regulation of microRNA expression in transplanted pancreatic islets. J Transplant. 2012; 2012: 723614.
45. Pileggi A, Klein D, Fotino C etal. MicroRNAs in islet immunobiology and transplantation. Immunol Res. 2013; 57: 185-196.
46. Karolina DS, Armugam A, Tavintharan S etal. MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS ONE. 2011; 6: e22839.
47. Georges M, Coppieters W, Charlier C. Polymorphic miRNA-mediated gene regulation: Contribution to phenotypic variation and disease. Curr Opin Genet Dev. 2007; 17: 166-176.
48. Georges M, Clop A, Marcq F etal. Polymorphic microRNA-target interactions: A novel source of phenotypic variation. Cold Spring Harb Symp Quant Biol. 2006; 71: 343-350.
49. Duggirala R, Blangero J, Almasy L etal. A major locus for fasting insulin concentrations and insulin resistance on chromosome 6q with strong pleiotropic effects on obesity-related phenotypes in nondiabetic Mexican Americans. Am J Hum Genet. 2001; 68: 1149-1164.
50. Villuendas G, Botella-Carretero JI, López-Bermejo A etal. The ACAA-insertion/deletion polymorphism at the 3'UTR of the IGF-I receptor gene is associated with type 2 diabetes and surrogate markers of insulin resistance. Eur J Endocrinol. 2006; 155: 331-336.
51. Lv K, Guo Y, Zhang Y, Wang K, Jia Y, Sun S. Allele-specific targeting of hsa-miR-657 to human IGF2R creates a potential mechanism underlying the association of ACAA-insertion/deletion polymorphism with type 2 diabetes. Biochem Biophys Res Commun. 2008; 374: 101-105.
52. Taskinen MR. Diabetic dyslipidaemia: From basic research to clinical practice. Diabetologia. 2003; 46: 733-749.
53. Kalmár T, Seres I, Balogh Z, Káplár M, Winkler G, Paragh G. Correlation between the activities of lipoprotein lipase and paraoxonase in type 2 diabetes mellitus. Diabetes Metab. 2005; 31: 574-580.
54. Richardson K, Nettleton JA, Rotllan N etal. Gain-of-function lipoprotein lipase variant rs13702 modulates lipid traits through disruption of a microRNA-410 seed site. Am J Hum Genet. 2013; 92: 5-14.
55. Batterham RL, Bloom SR. The gut hormone peptide YY regulates appetite. Ann N Y Acad Sci. 2003; 994: 162-168.
56. Doucet E, Laviolette M, Imbeault P, Strychar I, Rabasa-Lhoret R, Prud'homme D. Total peptide YY is a correlate of postprandial energy expenditure but not of appetite or energy intake in healthy women. Metabolism. 2008; 57: 1458 -1464.
57. Cai G, Cole SA, Butte NF, Voruganti VS, Comuzzie AG. Genome-wide scan revealed genetic loci for energy metabolism in Hispanic children and adolescents. Int J Obes. 2008; 32: 579-585.
58. Pérusse L, Rice T, Chagnon YC etal. A genome-wide scan for abdominal fat assessed by computed tomography in the Quebec Family Study. Diabetes. 2001; 50: 614-621.
59. Torekov SS, Larsen LH, Glümer C etal. Evidence of an association between the ARG72 allele of the peptide YY and increased risk of type 2 diabetes. Diabetes. 2005; 54: 2261-2265.
60. Shih PA, Wang L, Chiron S etal. Peptide YY (PYY) gene polymorphisms in the 3'-untranslated and proximal promoter regions regulate cellular gene expression and PYY secretion and metabolic syndrome traits in vivo. J Clin Endocrinol Metab. 2009; 94: 4557-4566.
61. Boey D, Heilbronn L, Sainsbury A etal. Low serum PYY is linked to insulin resistance in first-degree relatives of subjects with type 2 diabetes. Neuropeptides. 2006; 40: 317-324.
62. Siddiq A, Gueorguiev M, Samson C etal. Single nucleotide polymorphisms in the neuropeptide Y2 receptor (NPY2R) gene and association with severe obesity in French white subjects. Diabetologia. 2007; 50: 574-584.
63. 2+ channels are associated with insulin resistance and type 2 diabetes in Pima Indians. Diabetes. 2007; 56: 3089-3094.
64. Siitonen N, Pulkkinen L, Lindstrom J etal. Association of ADIPOQ gene variants with body weight, type 2 diabetes and serum adiponectin concentrations: The Finnish Diabetes Prevention Study. BMC Med Genet. 2011; 12: 5.
65. Wang X, Zhang S, Chen Y etal. APM1 gene variants -11377C/G and 4545G/C are associated respectively with obesity and with non-obesity in Chinese type 2 diabetes. Diabetes Res Clin Pract. 2009; 84: 205-210.
66. Filippi E, Sentinelli F, Trischitta V etal. Association of the human adiponectin gene and insulin resistance. Eur J Hum Genet. 2004; 12: 199-205.
67. Tan MS, Chang SY, Chang DM etal. Association of resistin gene 3'-untranslated region +62G→A polymorphism with type 2 diabetes and hypertension in a Chinese population. J Clin Endocrinol Metab. 2003; 88: 1258-1263.
68. Jiang ZS, Wang SX, Jia HX, Wang J, Liu YT. Association of toll-like receptor 4 polymorphisms with type 2 diabetes mellitus. Inflammation. 2013; 36: 251-257.
69. Zhao X, Ye Q, Xu K etal. Single-nucleotide polymorphisms inside microRNA target sites influence the susceptibility to type 2 diabetes. J Hum Genet. 2013; 58: 135-141.
70. Di Paola R, Frittitta L, Miscio G etal. A variation in 3'UTR of hPTP1B increases specific gene expression and associates with insulin resistance. Am J Hum Genet. 2002; 70: 806-812.
71. Malodobra M, Pilecka A, Gworys B, Adamiec R. Single nucleotide polymorphisms within functional regions of genes implicated in insulin action and association with the insulin resistant phenotype. Mol Cell Biochem. 2011; 349: 187-193.
72. Warensjö E, Ingelsson E, Lundmark P etal. Polymorphisms in the SCD1 gene: Associations with body fat distribution and insulin sensitivity. Obesity. 2007; 15: 1732-1740.
73. Aulchenko YS, Pullen J, Kloosterman WP etal. LPIN2 is associated with type 2 diabetes, glucose metabolism, and body composition. Diabetes. 2007; 56: 3020-3026.
74. Gaens KHJ, Van Der Kallen CJH, Van Greevenbroek MMJ, Feskens EJ, Stehouwer CD, Schalkwijk CG. Receptor for advanced glycation end product polymorphisms and type 2 diabetes: the CODAM study. Ann NY Acad Sci. 2008; 1126: 162-165.
75. Paladini F, Adinolfi V, Cocco E etal. Gender-dependent association of type 2 diabetes with the vasoactive intestinal peptide receptor 1. Gene. 2012; 493: 278-281.
76. Strawbridge RJ, Dupuis J, Prokopenko I etal. Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. Diabetes. 2011; 60: 2624-2634.
77. Morris A, Voight BF, Teslovich TM etal. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet. 2012; 44: 981-990.
78. Ye Q, Zhao X, Xu K etal. Polymorphisms in lipid metabolism related miRNA binding sites and risk of metabolic syndrome. Gene. 2013; 528: 132-138.
79. Hoffmeister A, Tuennemann J, Sommerer I etal. Genetic and biochemical evidence for a functional role of BACE1 in the regulation of insulin mRNA expression. Obesity. 2013; 21: E626-633.
80. Kamiyama M, Kobayashi M, Araki S etal. Polymorphisms in the 3'UTR in the neurocalcin delta gene affect mRNA stability, and confer susceptibility to diabetic nephropathy. Hum Genet. 2007; 122: 397-407.
81. Keene KL, Mychaleckyj JC, Smith SG etal. Association of the distal region of the ectonucleotide pyrophosphatase/phosphodiesterase 1 gene with type 2 diabetes in an African-American population enriched for nephropathy. Diabetes. 2008; 57: 1057-1062.
82. Zhang H, Jia Y, Cooper JJ, Hela T, Zhang Z, Elbein SC. Common variants in glutamine: Fructose-6-phosphate amidotransferase 2 (GFPT2) gene are associated with type 2 diabetes, diabetic nephropathy, and increased GFPT2 mRNA levels. J Clin Endocrinol Metab. 2004; 89: 748-755.
83. Chanock SJ, Manolio T, Boehnke M etal. Replicating genotype-phenotype associations. Nature. 2007; 447: 655-660.
84. Hwang HW, Wentzel EA, Mendell JT. A hexanucleotide element directs microRNA nuclear import. Science. 2007; 315: 97-100.
85. Gibbings DJ, Ciaudo C, Erhardt M, Voinnet O. Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. Nat Cell Biol. 2009; 11: 1143-1149.
86. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 9: 654-659.
87. Mencía A, Modamio-Høybjør S, Redshaw N etal. Mutations in the seed region of human miR-96 are responsible for nonsyndromic progressive hearing loss. Nat Genet. 2009; 41: 609-613.
88. Chen JM, Ferec C, Cooper DN. A systematic analysis of disease-associated variants in the 3' regulatory regions of human protein-coding genes I: General principles and overview. Hum Genet. 2006; 120: 1-21.
89. Chen K, Song F, Calin GA, Wei Q, Hao X, Zhang W. Polymorphisms in microRNA targets: A gold mine for molecular epidemiology. Carcinogenesis. 2008; 29: 1306-1311.
90. Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5'UTR as in the 3'UTR. Proc Natl Acad Sci USA. 2007; 104: 9667-9672.
91. Mishra PJ. MicroRNA polymorphisms: A giant leap towards personalized medicine. Per Med. 2009; 6: 119-125.